朱婷,何秋毅,许晨舒,陈杰
ZHU Ting,HE Qiuyi,XU Chenshu,CHEN Jie

• 1:中山大学附属第一医院药学部
• 2:中山大学药学院

摘要(Abstract)：

目的了解某三甲医院门诊系统性红斑狼疮患者的用药情况。方法随机抽取某院2013-05~2013-10诊断为系统性红斑狼疮的门诊处方973张,收集患者的一般资料和用药情况并进行统计分析。结果 973张处方中,女性856人,男性117人。采用单药治疗的红斑狼疮患者占总人数的13.1%(n=127),采用2,3,4和超过4种药物联合治疗的红斑狼疮患者分别占19.6%,5.7%,21.5%,40.1%。免疫抑制剂、糖皮质激素和抗疟药是使用最多的3类药物,占总处方的比例分别为74.0%,68.4%,47.2%。泼尼松的使用比例最高(55.6%),其次分别是羟氯喹(47.2%),甲氨蝶呤(36.3%),甲泼尼松(12.7%)和环孢素(12.2%)。结论该院门诊红斑狼疮患者的用药基本符合指南的推荐,但临床医生仍需注意给药方案的个体化以及糖皮质激素和免疫抑制剂的合理应用。
OBJECTIVE To evaluate the drug prescribing pattern for systemic lupus erythematosus( SLE) at the outpatient clinic in a tertiary care teaching hospital. METHODS A total of 973 prescriptions from patients diagnosed with SLE for treatment were randomly selected in the chosen outpatient health facility between May and October 2013. Data on demographic characteristics and prescribed medication were collected and analyzed.RESULTS Analysis of the data revealed that more female( n = 856) than male( n= 117) were diagnosed with SLE. Of the 973 patients studied,13. 1%( n = 127) were on monotherapy and 86. 9%( n = 846) on combination therapy. Of the patients on combination therapy,19.6%( n = 191),25.7%( n = 250),21.5%( n = 209) and 20.2%( n =197) were on 2,3,4 and more than 4 drugs,respectively. The most commonly used therapeutic drug groups were immunosuppressant( 74.0%),glucocorticoids( 68.4%),and the antimalarial agent hydroxychloroquine( 47.2%). Overall,prednisone were the most commonly prescribed( 55. 6%) followed by hydroxychloroquine( 47. 2%),methotrexate( 36. 3%),meprednisone( 12. 7%),and ciclosporin( 12.2%). CONCLUSION Prescribing pattern of therapeutic agents against SLE showed adherence to existing evidence based guidelines. Special attention should be paid for the adjustment of individualized dosage regimen and rational usage of glucocorticoids and immunosuppressive agents in the treatment of SLE.

关键词(KeyWords)： 用药分析;系统性红斑狼疮;门诊患者
prescription patterns;systemic lupus erythematosus;outpatients

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 朱婷,何秋毅,许晨舒,陈杰
ZHU Ting,HE Qiuyi,XU Chenshu,CHEN Jie

参考文献(References)：

• [1]Jordan N,Lutalo PM,D'Cruz DP.Novel therapeutic agents in clinical development for systemic lupus erythematosus[J].BMC Med,2013,11:120.
• [2]Forabosco P,Gorman JD,Cleveland C,et al.Meta-analysis of genome-wide linkage studies of systemic lupus erythematosus[J].Genes Immun,2006,7(7):609-614.
• [3]Danchenko N,Satia JA,Anthony MS.Epidemiology of systemic lupus erythematosus:a comparison of worldwide disease burden[J].Lupus,2006,15(5):308-318.
• [4]Bertsias G,Ioannidis JP,Boletis J,et al.EULAR recommendations for the management of systemic lupus erythematosus.Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics[J].Ann Rheum Dis,2008,67(2):195-205.
• [5]Guidelines for referral and management of systemic lupus erythematosus in adults.American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines[J].Arthritis Rheum,1999,42(9):1785-1796.
• [6]Touma Z,Urowitz MB,Gladman DD.Systemic lupus erythematosus:an update on current pharmacotherapy and future directions[J].Expert Opin Biol Ther,2013,13(5):723-737.
• [7]Runkel L,Stacey J.Lupus clinical development:will belimumab's approval catalyse a new paradigm for SLE drug development[J].Expert Opin Biol Ther,2014,14(4):491-501.
• [8]Sekigawa I,Fujishiro M,Yamaguchi A,et al.A new hypothesis of the possible mechanisms of gender differences in systemic lupus erythematosus[J].Clin Exp Rheumatol,2010,28(3):419-423.
• [9]Slae M,Heshin-Bekenstein M,Simckes A,et al.Female polysomy-X and systemic lupus erythematosus[J].Semin Arthritis Rheum,2014,43(4):508-512.
• [10]Raza K,Hardy R,Cooper MS.The 11beta-hydroxysteroid dehydrogenase enzymes--arbiters of the effects of glucocorticoids in synovium and bone[J].Rheumatology(Oxford),2010,49(11):2016-2023.
• [11]Abarientos C,Sperber K,Shapiro DL,et al.Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy[J].Expert Opin Drug Saf,2011,10(5):705-714.
• [12]Kang I,Park SH.Infectious complications in SLE after immunosuppressive therapies[J].Curr Opin Rheumatol,2003,15(5):528-534.
• [13]Katz SJ,Russell AS.Re-evaluation of antimalarials in treating rheumatic diseases:re-appreciation and insights into new mechanisms of action[J].Curr Opin Rheumatol,2011,23(3):278-281.
• [14]Rodriguez-Hurtado FJ,Saez-Moreno JA,Rodriguez-Ferrer JM.Maculopathy in patient with systemic lupus erythematosus treated with hydroxychloroquine[J].Reumatol Clin,2012,8(5):280-283.
• [15]Maremanda KP,Khan S,Jena G.Zinc protects cyclophosphamide-induced testicular damage in rat:involvement of metallothionein,tesmin and Nrf2[J].Biochem Biophys Res Commun,2014,445(3):591-596.